Crede Blasts Tobacco Co. In $250M Suit Over China JV

By Daniel Siegal (April 27, 2016, 11:45 PM EDT) -- 22nd Century, a genetic engineering company specializing in low-nicotine tobacco, was hit with a $250 million contract suit in New York federal court Tuesday by its largest investor, private equity fund Crede CG, which alleges 22nd Century cut it out of a lucrative Chinese joint venture.

Crede CG fund Crede CG III Ltd. filed suit against 22nd Century Group Inc. for breach of contract, alleging the Nevada-based plant biotechnology company intentionally caused a potentially gangbusters joint venture they had formed to sell genetically modified tobacco in China to become a "total failure" in a scheme to keep the opportunity for itself....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


Subscribers Only

Nature of Suit

Subscribers Only


Subscribers Only

Date Filed

Subscribers Only

Law Firms

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!